Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Sep. 1, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:

• Wells Fargo 21st Annual Healthcare Conference
  Tuesday, September 8, 2026
  1x1 investor meetings
  Boston, MA
  
  
• Citi Biopharma Back to School Summit
  Wednesday, September 9, 2026
  Fireside chat at 10:00 a.m. ET
  New York, NY
  
  
• Cantor Global Healthcare Conference 2026
  Thursday, September 10, 2026
  Fireside chat at 8:35 a.m. ET
  New York, NY
  Webcast Link
  
  
• Morgan Stanley 24th Annual Global Healthcare Conference
  Monday, September 14 & Wednesday, September 16, 2026
  Fireside chat at 9:15 a.m. EDT on Wednesday
  New York, NY
  Webcast Link
  
  
• Baird Global Healthcare Conference
  Tuesday, September 15, 2026
  Fireside chat at 10:15 a.m. ET
  New York, NY
  
  
• H.C. Wainwright 28th Annual Global Investment Conference
  Wednesday, September 16, 2026
  Fireside chat at 10:30 a.m. ET
  New York, NY
  
  
• Deutsche Bank 2026 Healthcare Summit
  Thursday, September 17, 2026
  1x1 investor meetings
  New York, NY

Live webcasts of the Cantor and Morgan Stanley fireside chats can be accessed via the Events and Presentations section of the Faeth website at investors.faeththerapeutics.com. Replays will be available for approximately 90 days following the event.

About Faeth Therapeutics

Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.D. For more information, please visit www.faeththerapeutics.com and follow the Company on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260901235886/en/

Investor Contact:
Matthew Biegler, SVP, Investor Relations
matt@faeththerapeutics.com

Media Contact:
Patrick Schmidt, Consort Partners
faeththerapeutics@consortpartners.com

Source: Faeth Therapeutics